COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA

被引：1
|
作者：
Alhammad, A. [1 ]
Lecca, Garrido S. [2 ]
机构：
[1] King Abdul Aziz Med City, Riyadh, Saudi Arabia
[2] Bristol Myers Squibb, Dubai, U Arab Emirates
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2254
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
下载
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [42] Atezolizumab in non-squamous non-small cell lung cancer
    Akamine, Takaki
    Toyokawa, Gouji
    Tagawa, Tetsuzo
    Seto, Takashi
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3155 - S3159
  • [43] The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in Germany.
    Bischoff, H.
    Hermes, A.
    Gatzemeier, U.
    Heigener, D. F.
    Cesaro-Tadic, S.
    Walzer, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Kuhlmann, A.
    Schmidt, T.
    Treskova, M.
    Golpon, H.
    Welte, T.
    Von der Schulenburg, J. -Graf
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2303
  • [45] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [46] Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
    Hu, Shanlian
    Tang, Zhiliu
    Harrison, James P.
    Hertel, Nadine
    Penrod, John R.
    May, Jessica R.
    Juarez-Garcia, Ariadna
    Holdgate, Orban
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 273 - 284
  • [47] Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
    Shanlian Hu
    Zhiliu Tang
    James P. Harrison
    Nadine Hertel
    John R. Penrod
    Jessica R. May
    Ariadna Juarez-Garcia
    Orban Holdgate
    PharmacoEconomics - Open, 2023, 7 : 273 - 284
  • [48] Management and treatment costs of non-squamous metastatic or locally advanced non-small cell lung cancer
    Pruszko, Cezary
    Jachimowicz, Michal
    Kalinowska, Agnieszka
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (02): : 63 - 67
  • [49] WORDS (EXCLUDING TATLE AND AUTHORS: 300) TITLE: COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE TREATMENT OF SECOND-LINE ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
    Gonzalez Garcia, P.
    Felip, E.
    Garrido, P.
    Trigo, J.
    Ortega-Joaquin, N.
    Echave, M.
    Jimenez, S.
    Oyaguez, I
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A733
  • [50] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
12345